WO2006110728A3 - Immunogenic cmv tegument aggregates - Google Patents

Immunogenic cmv tegument aggregates Download PDF

Info

Publication number
WO2006110728A3
WO2006110728A3 PCT/US2006/013451 US2006013451W WO2006110728A3 WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3 US 2006013451 W US2006013451 W US 2006013451W WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3
Authority
WO
WIPO (PCT)
Prior art keywords
tegument aggregates
aggregates
provides
present
cmv
Prior art date
Application number
PCT/US2006/013451
Other languages
French (fr)
Other versions
WO2006110728A2 (en
Inventor
Earl R Kern
Mark Neal Prichard
William J Britt
Original Assignee
Uab Research Foundation
Earl R Kern
Mark Neal Prichard
William J Britt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Earl R Kern, Mark Neal Prichard, William J Britt filed Critical Uab Research Foundation
Publication of WO2006110728A2 publication Critical patent/WO2006110728A2/en
Publication of WO2006110728A3 publication Critical patent/WO2006110728A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides for cytomegalovirus protein tegument aggregates, pharmaceutical compositions, and the use thereof. The present invention provides for methods for anti-viral drug screening, production of CMV antigenic proteins, recombinant protein expression, immunogenic compounds such as CMV tegument aggregates with or without additional haptens, and vaccines useful for raising an immune response in an animal.
PCT/US2006/013451 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates WO2006110728A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67026205P 2005-04-12 2005-04-12
US60/670,262 2005-04-12

Publications (2)

Publication Number Publication Date
WO2006110728A2 WO2006110728A2 (en) 2006-10-19
WO2006110728A3 true WO2006110728A3 (en) 2007-12-06

Family

ID=37087624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013451 WO2006110728A2 (en) 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates

Country Status (1)

Country Link
WO (1) WO2006110728A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068850A1 (en) 2008-12-12 2010-06-17 Georgetown University Methods of diagnosing and treating cancer
ES2635727T3 (en) 2009-04-30 2017-10-04 University Of Rochester Antibodies against DC-STAMP
WO2011056975A2 (en) 2009-11-06 2011-05-12 Howard Hughes Medical Institute Genetically encoded calcium indicators and methods of use
JP2014531896A (en) 2011-08-30 2014-12-04 ザ ユーエービー リサーチ ファンデーション Mycobacterium tuberculosis porins and toxins and related methods
US10684282B2 (en) 2011-10-07 2020-06-16 Howard Hughes Medical Institute Genetically encoded biosensors
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
US9518980B2 (en) 2012-10-10 2016-12-13 Howard Hughes Medical Institute Genetically encoded calcium indicators
US20180153976A1 (en) * 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
BR112020023167A2 (en) 2018-05-14 2021-02-09 Werewolf Therapeutics, Inc. activatable cytokine polypeptides and methods of using these
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
MX2021013766A (en) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Separation moieties and methods and use thereof.
MX2022005666A (en) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof.
IL298295A (en) 2020-05-19 2023-01-01 Werewolf Therapeutics Inc Activatable il-12 polypeptides and methods of use thereof
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
EP4217496A2 (en) 2020-09-23 2023-08-02 Howard Hughes Medical Institute Genetically encoded calcium indicators (gecis) and methods of making and using
CA3228927A1 (en) 2021-08-18 2023-02-23 William Winston Activatable inteferon polypeptides and methods of use thereof
WO2023196897A1 (en) 2022-04-07 2023-10-12 Werewolf Therapeutics Inc. Il-12 prodrugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAIR ET AL.: "The products of human cytomegalovirus genes UL23, UL24, Ul43 and US22 are tegument components", JOURNAL OF GENERAL VIROLOGY, vol. 83, 2002, pages 1315 - 1324, XP008091914 *
PRICHARD ET AL.: "Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis", JOURNAL OF VIROLOGY, vol. 79, no. 24, 2005, pages 15494 - 15502, XP008092465 *
SEVERI ET AL.: "Human cytomegalovirus nuclear and cytoplasmic dense bodies", J. ARCH. VIROL., vol. 123, no. 1-2, March 1992 (1992-03-01), pages 193 - 207, XP008091384 *

Also Published As

Publication number Publication date
WO2006110728A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006110728A3 (en) Immunogenic cmv tegument aggregates
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
CY1121132T1 (en) FULLY-HUMAN MONOCLONE ANTIBODIES ANTI-vap-1
WO2011008974A3 (en) Rsv f protein compositions and methods for making same
WO2004075829A3 (en) Adjuvanted influenza vaccine
CY1114244T1 (en) VEGF COMPONENT COMPONENTS FOR SUITABLE INTERVENTAL ADMINISTRATION
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2016116905A9 (en) Cmv antigens and uses thereof
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
WO2009135199A3 (en) Vaccine compositions and methods
WO2011056721A3 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
WO2006047728A3 (en) Bmp gene and fusion protein
WO2005007673A3 (en) Immunogenic peptides
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749735

Country of ref document: EP

Kind code of ref document: A2